In Bloomberg Law, MBHB Partner Kevin Noonan discusses the Federal Circuit’s to reassess the Patent Trial and Appeal Board’s findings on CRISPR-Cas9 gene editing technology, repositioning a coalition of universities and Nobel laureates to win credit and patent rights for the breakthrough invention. View the article here.
